KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment

The Prostate ◽  
2014 ◽  
Vol 74 (12) ◽  
pp. 1222-1230 ◽  
Author(s):  
Siebren Dijkstra ◽  
Gisele H. J. M. Leyten ◽  
Sander A. Jannink ◽  
Hans de Jong ◽  
Peter F. A. Mulders ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Peripheral Blood Mononuclear Cell ◽  
Cancer Patients ◽  
Mononuclear Cell ◽  
Peripheral Blood ◽  
Castration Resistant Prostate Cancer ◽  
Peripheral Blood Mononuclear ◽  
Castration Resistant ◽  
Docetaxel Treatment ◽  
Mononuclear Cell Fraction

Her2/neu Expression by Reverse Transcriptase-Polymerase Chain Reaction in the Peripheral Blood of Prostate Cancer Patients

2007 ◽  
Vol 93 (5) ◽  
pp. 467-472 ◽  
Author(s):  
Ana Paula Fantinato ◽  
Marcos Tobias-Machado ◽  
Fernando Fonseca ◽  
Jorge Luiz Freire Pinto ◽  
Marcelo Langer Wroclawski ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Peripheral Blood Mononuclear Cell ◽  
Cancer Patients ◽  
Mononuclear Cell ◽  
Peripheral Blood ◽  
Cell Fraction ◽  
Peripheral Blood Mononuclear ◽  
Psa Progression ◽  
Mononuclear Cell Fraction

Background/Aims Evaluation of Her2/neu expression in the peripheral blood mononuclear cell fraction of prostate cancer patients by RT-PCR may afford an opportunity for the detection of circulating tumor cells and thus serve as a marker of micrometastatic disease. Methods We studied Her2/neu expression by reverse transcriptase-polymerase chain reaction in peripheral blood mononuclear cell fraction samples of 21 controls and serially in 43 patients with prostate cancer. Results None of the 21 controls expressed Her2/neu whereas 23.25% (95% CI, 11.75–38.63) of the patients were positive at entry into the study, and 65.11% (95% CI, 49.07–78.99) of them had at least one positive result during the follow-up period. Her2/neu positivity at study entry did not correlate significantly with PSA level, Gleason score, clinical stage or time to PSA progression. When we analyzed only patients with advanced disease, we observed a trend towards a shorter time to PSA progression in patients with at least one positive Her2/neu result during the follow-up (log-rank test, P = 0.08). Conclusions We conclude that Her2/neu expression in the peripheral blood mononuclear cell fraction of prostate cancer patients is frequent and therefore this assay may potentially be useful to detect the presence of micrometastatic disease in men with prostate cancer and for monitoring patients enrolled in trastuzumab-based therapeutic protocols.

Chemotherapy-induced fatigue is associated with changes in gene expression in the peripheral blood mononuclear cell fraction of patients with locoregional breast cancer

2018 ◽  
Vol 27 (7) ◽  
pp. 2479-2486 ◽  
Author(s):  
Barbara Bonaparte Ribas de Alcântara ◽  
Felipe Melo Cruz ◽  
Fernando Luiz Affonso Fonseca ◽  
Beatriz da Costa Aguiar Alves ◽  
Matheus Moreira Perez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Peripheral Blood Mononuclear Cell ◽  
Mononuclear Cell ◽  
Peripheral Blood ◽  
Cell Fraction ◽  
Peripheral Blood Mononuclear ◽  
Mononuclear Cell Fraction

scholarly journals No evidence of mycoplasmas in peripheral blood mononuclear cell fraction of HIV-infected patients

Infection ◽  
1994 ◽  
Vol 22 (3) ◽  
pp. 204-206 ◽  
Author(s):  
F. van Kuppeveld ◽  
W. Melchers ◽  
J. Kissing ◽  
J. van der Logt ◽  
J. Galama
Keyword(s):  
Peripheral Blood Mononuclear Cell ◽  
Mononuclear Cell ◽  
Peripheral Blood ◽  
Cell Fraction ◽  
Peripheral Blood Mononuclear ◽  
Mononuclear Cell Fraction

scholarly journals Epigenetic markers-based breast cancer early detection method development

2020 ◽  
Vol 58 (4) ◽  
pp. 29-35
Author(s):  
T. GONCHAROVA ◽  
D. KAIDAROVA ◽  
N. OMARBAYEVA ◽  
A. ASKANDIROVA ◽  
M. ORAZGALIYEVA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Early Detection ◽  
Peripheral Blood Mononuclear Cell ◽  
Cancer Patients ◽  
Mononuclear Cell ◽  
Peripheral Blood ◽  
Intergenic Region ◽  
Detection Method ◽  
Peripheral Blood Mononuclear

Relevance: According to the International Agency for Research on Cancer (IARС), breast cancer ranks 1st-2nd among other cancers globally [1], including Kazakhstan [2]. In Kazakhstan, the annual growth in breast cancer incidence exceeds 26.6%. In 2018-2019, breast cancer was the 3rd most common cause of cancer death in Kazakhstan, accounting for 8.7-8.1 percent, respectively. Early detection of breast cancer remains an acute issue. In particular, early detection should be improved. Epigenetic studies of cancer patients confirm that epigenetic biomarkers could be used as early cancer diagnostic markers, including breast cancer. The study aimed to find specific diagnostic markers by methylation profiling of peripheral blood mononuclear cell (PBMC) DNA in breast cancer patients. Results: Plasma samples of the Kazakhstani population with breast cancer possessed mononuclear cell methylation markers in CpG islets associated with JAM3, C17orf64, MSC, and C7orf51 genes and the CpG islet associated with the intergenic region on chromosome 5, chr5: 77,208,034-77,329,434, which were missing in healthy individuals. These biomarkers allow differentiating breast cancer from other cancers with a specificity of 0.91 and a sensitivity of 0.94 compared to methylation data from open DNA methylation databases (for Illumina 450K): TCGA, GSE40279, GSE61496, GSE76269 и GSE66836. Conclusion: Early breast cancer detection method using peripheral blood mononuclear cell DNA methylation profile, namely in CpG islets associated with JAM3, C17orf64, MSC, and C7orf51 genes and the CpG islet associated with the intergenic region on chromosome 5, chr5: 77,208,034-77,329,434 is enough specific and sensitive to use it in breast cancer screening.

ARV7 and ARFL mRNA in blood to predict androgen receptor inhibitors and docetaxel response in castration-resistant prostate cancer patients.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 207-207
Author(s):  
Mercedes Marin ◽  
Natalia Jiménez ◽  
Òscar Reig ◽  
Maria Verónica Pereira ◽  
Maria Mila ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Mononuclear Cells ◽  
Specific Antigen ◽  
Post Treatment ◽  
Mrna Levels ◽  
Castration Resistant Prostate Cancer ◽  
Peripheral Blood Mononuclear ◽  
Castration Resistant ◽  
Docetaxel Treatment

207 Background: The constitutively active androgen receptor (AR) variant 7 ( ARV7) has been associated with AR inhibitors (ARI) resistance, while its role predicting taxanes response remains controversial. We investigated the association between ARV7 and AR full length ( ARFL) expression pre-docetaxel treatment and changes pre- post-treatment in blood with docetaxel activity in metastatic castration-resistant prostate cancer (mCRPC) patients. Methods: ARV7 and ARFL mRNAs were tested by quantitative reverse-transcription PCR in peripheral blood mononuclear cells (PBMC) from mCRPC patients. Measurements were performed before docetaxel treatment and in a subset of patients also post-treatment. A cohort of patients treated with ARI was also included as a control. Results: We included 105 patients: 50 with treated with docetaxel and 55 with ARI. In 28 patients ARV7 and ARFL were evaluated pre and post-docetaxel. High ARV7 correlated with longer PSA-PFS (HR 0.42; 95%CI 0.18-0.99; P= 0.049), radiologic (RX)-PFS (HR 0.32; 95%CI 0.14-0.72; P= 0.006), and overall survival (OS) (HR 0.41; 95%CI 0.18-0.91; P= 0.028) to docetaxel. When relativizing to ARFL we observed that high ARV7/ ARFL ratio also correlated with a better PSA-PFS (HR 0.38; 95%CI 0.17-0.85; P= 0.0179) and RX-PFS (HR 0.43; 95%CI 0.2-0.91; P= 0.0273) to docetaxel. High ARV7 and ARV7/ ARFL were correlated with lower prostatic-specific antigen (PSA) progression-free survival (PFS) to ARI therapy (HR 2.18; 95%CI 1.03-4.6; P= 0.043 and HR 3.84; 95%CI 1.54-9.4; P= 0.004, respectively). ARV7/ ARFL and treatment- ARV7/ARFL interaction were independently associated with better PSA-PFS to docetaxel treatment and lower PSA-PFS to ARI. The increase of ARV7 mRNA levels after docetaxel treatment was indicative of longer OS (HR 0.07; 95%CI 0.008-0.57; P= 0.013). Conclusions: High ARV7 expression and ARV7/ ARFL ratio evaluated in PBMC pre-docetaxel are associated with better clinical outcome in mCRPC patients and lower ARI benefit. The increase of ARV7 levels after docetaxel exposure was also indicative of better outcome.

Sign in / Sign up

Export Citation Format

Share Document